| 证券代码：603108 证券简称：润达医疗 | 公告编号：临 | 2025-009 | | --- | --- | --- | | 转债简称：润达转债 转债代码：113588 | | | 上海润达医疗科技股份有限公司 股东股份部分解质押及质押延期购回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海润达医疗科技股份有限公司（以下简称"公司"）接到股东刘辉先生通 知，获悉其在 2025 年 4 月 22 日，将原质押给中信建投证券股份有限公司（以下 简称"中信建投"）的 11,630,000 股公司股份办理了部分解除质押及质押延期购 回的手续，本次解质押股份为 2,000,000 股，延期购回股份为 9,630,000 股。原质 押情况详见公司临时公告（编号：临 2024-007）。本次办理的事项具体如下： 截至公告披露日，股东刘辉先生及其一致行动人朱文怡女士所持公司股份均 为无限售条件流通股，累计质押股份情况如下： | 股东名 | | 持股比 | 本次质押前 | 本次质押后 | 占其所 | 占公司 ...

上海润达医疗科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 可转债发行上市概况 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-007 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限公司于 2020 年 6 月 17 日公开发行了 5,500,000 张（550,000 手）可转换公司债券，每张面值 100 元，发行总额 55,000 万元，发行期限 6 年， 票面利率分别为：第一年 0.3%、第二年 0.6%、第三年 1.0%、第四年 1.5%、第 五年 1.8%、第六年 2.0%。 累计转股情况：截至 2025 年 3 月 31 日，累计人民币 315,475,000 元的"润 达转债"转换成公司股份，占可转债发行总量的 57.3591%，累计转股数 量 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-008 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2023 年度股东大会审议通过：自 2024 年 5 月 23 日至 2024 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 421,300 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：五家全资子公司：杭州润达、惠中医疗、惠中生物、鑫 海润邦、青岛益信；六家控股子公司：合肥润达、云南康泰、武汉尚检、 杭州怡丹、 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-006 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于与专业投资机构共同投资的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 为进一步推动公司战略发展和投资布局，上海润达医疗科技股份有限公司 （以下简称"公司"）与上海致凯资产管理有限公司（以下简称"致凯资产"）、 福州新投创业投资有限公司、福建贝瑞和康基因技术有限公司、上海福凯瑞康企 业管理咨询合伙企业（有限合伙）共同投资设立了福州新投致凯瑞康创业投资基 金合伙企业（有限合伙）（以下简称"合伙企业"或"基金"）。合伙企业的认缴 出资总额为 13,400 万元，其中公司作为有限合伙人认缴出资 2,680 万元，占 20.00%。具体内容详见公司于 2024 年 12 月 31 日在上海证券交易所网站（www.sse. com.cn）及《中国证券报》、《上海证券报 ...

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The report highlights significant stock performance in the sector, with the pharmaceutical and biotechnology sector (SW) rising by 2.71%, outperforming the CSI 300 index, and all sub-sectors showing positive growth, particularly in medical services [3][4]. - In the U.S., Tempus AI, a representative company in medical AI, saw a weekly increase of approximately 30% and over 160% year-to-date, driving the momentum of the medical AI concept. In China, companies like KingMed Diagnostics and Dian Diagnostics announced collaborations with DeepSeek, indicating a shift towards the commercialization of AI applications in healthcare [4][3]. - The report emphasizes investment opportunities in sub-sectors such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI Genomics, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% in the week of February 10-14, ranking 5th among 31 Shenwan primary industries. The CSI 300 index increased by 1.19% during the same period [5][6]. - All sub-sectors experienced growth, with medical services leading at +6.51%, followed by medical devices at +4.81%, and pharmaceutical commerce at +4.18% [5][6]. - Notable individual stock performances included Dian Diagnostics (+46.29%), Mian Health (+31.58%), and United Imaging (+27.33%) [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - The retail terminal drug sales scale in China is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, indicating a slowdown in growth due to demographic and economic factors [8]. - The report also notes significant collaborations, such as Baiyang Pharmaceutical's agreement with Roche for the exclusive marketing rights of a targeted cancer drug in mainland China [9][11]. Industry Data Tracking - The report tracks various industry metrics, including the basic medical insurance fund income, which reached 28,507.29 billion yuan in 2024, showing a year-on-year growth of 5% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of 25,298.50 billion yuan in 2024, with profit totals declining by 1.1% year-on-year [17].

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-005 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2023 年度股东大会审议通过：自 2024 年 5 月 23 日至 2024 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 421,300 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：三家全资子公司：青岛润达、鑫海润邦、青岛益信；两 家控股子公司：云南康泰、济南润达。被担保人非上市公司关联人。 本次担保金额及 ...

Summary of Runda Medical Conference Call Company Overview - **Company**: Runda Medical - **Industry**: Medical AI Key Points and Arguments Recent Developments in Medical AI - Runda AI has made significant advancements in the medical AI sector, collaborating with Huawei to launch an AI medical integration machine based on DeepMind technology and releasing the "Guardian Engine" smart body in partnership with West China Hospital [3][4] - The company introduced a dedicated model for interpreting test reports in 2021 and launched the first generation of its medical large model, "Good Doctor Assistant," in September 2023, with a second generation expected in September 2024 after 28 iterations [3][4] - Runda AI's integration machine simplifies hospital procurement processes and is particularly well-received by top provincial hospitals and city-level hospitals in economically developed regions [3][5] Market Expansion and Projections - Runda AI anticipates 2025 to be a breakthrough year for commercialization, driven by policy support and technological advancements, with plans to expand market coverage and deepen collaborations with top hospitals [3][7] - The company has signed contracts with over 100 tier-3 hospitals and is focusing on the clinical application of its products [3][7] AI Model Applications - The applications of Runda AI's medical large model are categorized into three levels: 1. Basic Q&A functions via hardware servers 2. Pre-set instruction functions for medical record writing and quality control 3. Comprehensive disease management models developed in collaboration with hospitals [10][15] Competitive Advantages - Runda AI is the first company to launch a medical integration machine, with a commercial process that began in 2023 and is accelerating in 2024. The company has developed multiple functional modules tailored for clinical scenarios, providing a competitive edge [9][16] - The integration machine's pricing strategy includes various versions based on functionality and computational power, targeting high-end hospitals with significant investment capabilities [6][8] Impact of AI Integration Machine - The release of the AI integration machine has improved customer education and trust in AI technology, streamlining procurement processes for hospitals [5][11] - Following the support from the National Health Commission for AI clinical use, there has been a surge in orders post-Chinese New Year, indicating a significant acceleration in AI business industrialization in 2025 compared to 2024 [11][12] Collaboration and Development - Runda AI collaborates closely with Huawei to design and plan new AI models, enhancing performance and optimizing human-computer interaction [19] - The company is also working on various specialized applications, such as emergency chest pain models with Qilu Hospital, aimed at improving rapid diagnosis capabilities and reducing misdiagnosis rates [14][17] Future Plans and Product Development - Runda AI is actively developing C-end products, including the "Health Xiao Mei" product in collaboration with Meinian Health, which has been launched in hundreds of health check-up institutions [23] - The company is also exploring further integration with Huawei's mobile and wearable devices, with plans for data integration and health risk analysis [24][26] Operational Efficiency - The deployment speed of AI models in hospitals has significantly improved, reducing the average delivery time from two months to three days through automation and process optimization [18] Additional Important Information - Runda AI's AI medical record generation model learns from hospital writing habits, allowing doctors to confirm records in seconds, significantly enhancing efficiency and quality [13] - The company is addressing the challenges of data integration for AI applications, emphasizing the need for structured data to provide accurate decision-making support [12]

Group 1 - The Fuzhou Xintou Zhi Kairuikang Venture Capital Fund Partnership (Limited Partnership) has been established recently, focusing on private equity investment, investment management, and asset management activities [1] - The company is co-funded by Run Da Medical and other entities, indicating a collaborative investment approach [1]

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-004 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2023 年度股东大会审议通过：自 2024 年 5 月 23 日至 2024 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 421,300 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：七家全资子公司：杭州润达、惠中医疗、惠中生物、浙 江中鼎、杭州铭和元、青岛润达、鑫海润邦；六家控股子公司：合肥润 达、武汉优科 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 42.91 million and 51.49 million yuan, a decrease of 22.18 million to 23.04 million yuan compared to the previous year, representing a decline of 81.16% to 84.30%[5] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 21.97 million and 26.36 million yuan, down by 12.30 million to 12.74 million yuan year-on-year, reflecting a decrease of 82.36% to 85.29%[5] - The financial data in the performance forecast has not been audited by a registered accountant[6] - The forecast data is preliminary and subject to change, with the final audited financial data to be disclosed in the company's annual report for 2024[11] - The company emphasizes that there are no significant uncertainties affecting the accuracy of this performance forecast[10] Historical Financial Performance - In 2023, the company achieved a total profit of 655.56 million yuan, with a net profit attributable to shareholders of the parent company of 273.30 million yuan[8] - The company reported earnings per share of 0.47 yuan for the year 2023[8] Factors Affecting Profitability - The significant decrease in net profit is primarily due to the impact of domestic macroeconomic conditions and centralized procurement policies, which affected business development and sales revenue[9] - Fixed costs, such as service costs and depreciation of fixed assets, have not decreased, leading to increased marginal costs and expenses[9] - The collection period for accounts receivable from end customers has lengthened, resulting in credit impairment losses that significantly impacted the net profit attributable to shareholders of the parent company[9]